Summary
A phase II study of vindesine was carried out in 33 patients with colorectal cancer and nine patients with esophageal cancer. With the exception of six previously untreated patients with esophageal cancer, all others were refractory to 5-FU-containing regimens, which included vincristine in ten patients. The initial dose of vindesine was 4 mg/m2 administered intravenously over 30 min every 2 weeks. Tumor regression >50% was seen in three patients (two colorectal and one esophageal) and an additional eight patients (six colorectal and two esophageal) achieved minor responses. Prior treatment with vincristine did not seem to influence response to vindensine. In general, the treatment with vindesine was well tolerated. The hematologic toxicity was acceptable and manifested mainly as moderate and transient neutropenia. The major nonhematologic toxicity was peripheral neuropathy, which became limiting. It occurred in 33% of patients who received two or more courses of vindesine. Because of the apparent antitumor activity and doselimiting neurotoxicity of vindesine in this study, further investigations of this compound should be conducted in combination chemotherapy programs for patients with metastatic gastrointestinal cancers.
Similar content being viewed by others
References
Bodey, G. P., Freireich, E. J.: Initial clinical studies of vindesine (desacetyl vinblastine amide sulfate). Proc AACR-ASCO 17, 128 (1976)
Carter, S. K., Friedman, M.: Integration of chemotherapy into combined modality treatment of solid tumors. II. Large bowel carcinoma. Cancer Treat. Rev. 1, 111 (1974)
Cullinan, G. J., Gerzon, K., Poore, G., et al.: Vinblastine modiffications: Desacetyl-VLB amides. (Abstr. 5C-19) In: Proceedings of the 9th International Congress of Chemotherapy, London (1975)
Douglas, H. O., Lavin, P. T., Moertel, C. G.: Nitrosoureas: Useful agents for the treatment of advanced gastrointestimal cancer. Cancer Treat. Rep. 60, 769 (1976)
Dyke, R. W., Nelson, R. L.: Phase I anti-cancer agents vindesine (desacetyl vinblastine amide sulfate). Cancer Treat. Rev. 4, 135 (1977)
Gehan, E. A.: A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika 52, 203 (1965)
Kaplan, E. L., Meier, P.: Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53, 457 (1958)
Larson, S., Lehane, D., Winston, A., et al.: The immunophar-macology of vindesine (VND) in man. Proc AACR-ASCO 19 405 (1978)
MacDonald, J. S., Kisner, D. F., Smyth, T., et al.: 5-Fluorouracil (5-FU), methyl CCNU and vincristine in the treatment of advanced colorectal cancer: Phase II study utilizing weekly 5-FU. Cancer Treat. Rep. 60, 1957 (1976)
Mathe, G., Misset, J. L., DeVassel, F., et al.,: Phase II Clinical trial with vindesine for remission induction in acute leukemia blastic crisis of chronic mycloid leukemia, lymphosarcoma and Hodgkin's disease: Absence of cross-resistance with vincristine. Cancer Treat. Rep. 62, 805 (1978)
Moertel, C. G.: Current concepts in cancer; chemotherapy of gastrointestinal cancer. N. Engl. J. Med. 299, 1049 (1978)
Nondavan, P., Lehane, D., Lane, M.: The immunopharmacology of vindesine. A rat model. Proc. AACR-ASCO 19, 220 (1978)
Ohnuma, T., Holland, J. F., Andrejczuk, A., et al.: Initial clinical and pharmacological studies with vindesine. Proc. AACR-ASCO 19, 129 (1978)
Smith, I. E., Hedley, D. W., Powles, T. J., McElwain, T. J.: Vindesine: A phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat. Rep. 62, 1427 (1978)
Todd, G. C., Gibson, W. R., Morton, D. M.: Toxicology of vindesine (desacetyl vinblastine amide) in mice, rats, and dogs. J. Toxicol. Environ. Health 1, 843 (1976)
Tom, C., Steinberg, P., Alikpala, A., et al.: Vindesine (DVA) responses in children with malignant diseases. Proc. AACR-ASCO 18, 239 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bedikian, A.Y., Valdivieso, M., Bodey, G.P. et al. Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemother. Pharmacol. 2, 263–266 (1979). https://doi.org/10.1007/BF00257192
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00257192